Avoid common mistakes on your manuscript.
Correction to: Invest New Drugs (2018) 36:96–102
PFS for chemotherapy treatment naïve PDAC (n = 12). The solid line shows PFS. The hashed line shows the 95% CI (confidence interval) for the curve
OS for chemotherapy treatment naïve PDAC (n = 12). The solid line shows OS. The hashed line shows the 95% CI for the curve
The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct. It was also noted that the upper value for the 95% CI had an error in both figures. Both graphs have been regenerated using the published PFS and OS data presented in Table 2 and the corrected 95% CIs are included. These changes do not impact the overall results of the data or the conclusions presented in the publication. We sincerely apologize for this oversight.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s10637-017-0525-1
Rights and permissions
About this article
Cite this article
Weiss, G.J., Blaydorn, L., Beck, J. et al. Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs 37, 797 (2019). https://doi.org/10.1007/s10637-019-00763-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-019-00763-x